| Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report |
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. The report highlights efforts to transform the lives of individuals and families affected by rare diseases, empower its employees, and make a meaningful impact on the communities it operates within and serves. |
globenewswire.com |
2025-05-14 20:30:00 |
Czytaj oryginał (ang.) |
| HENRY CATCHPOLE TAKES TO THE TRACK IN RARE HONDA NSX-R IN SWEDEN AHEAD OF BROAD ARROW'S FIRST EUROPEAN AUCTION |
HIGHLY COLLECTIBLE NSX-R TO FEATURE IN INAUGURAL BROAD ARROW CONCORSO D'ELEGANZA VILLA D'ESTE AUCTION ON 24-25 MAY HIGHLY COLLECTIBLE NSX-R TO FEATURE IN INAUGURAL BROAD ARROW CONCORSO D'ELEGANZA VILLA D'ESTE AUCTION ON 24-25 MAY |
globenewswire.com |
2025-05-08 12:01:00 |
Czytaj oryginał (ang.) |
| Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference |
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief financial officer and executive vice president, will participate in a fireside at Bank of America's 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT. |
globenewswire.com |
2025-05-07 21:00:00 |
Czytaj oryginał (ang.) |
| Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y |
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales. |
zacks.com |
2025-05-07 15:45:36 |
Czytaj oryginał (ang.) |
| Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript |
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript |
seekingalpha.com |
2025-05-07 03:31:54 |
Czytaj oryginał (ang.) |
| Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say |
The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-06 23:00:34 |
Czytaj oryginał (ang.) |
| Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates |
Ultragenyx (RARE) came out with a quarterly loss of $1.57 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $2.03 per share a year ago. |
zacks.com |
2025-05-06 22:10:46 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update |
First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million |
globenewswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| 5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates |
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings. |
zacks.com |
2025-05-05 14:15:41 |
Czytaj oryginał (ang.) |
| Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update |
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025. |
globenewswire.com |
2025-04-30 21:00:00 |
Czytaj oryginał (ang.) |
| Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release |
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-24 15:08:33 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
NOVATO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 36,831 restricted stock units of the company's common stock to 21 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-22 21:00:00 |
Czytaj oryginał (ang.) |
| Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline |
Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from Crysvita, Dojolvi, and Evkeeza fund innovation and buffer against financial volatility. Key catalysts include the FDA's Priority Review of UX111 for Sanfilippo syndrome type A, with a PDUFA date set for August 2025. |
seekingalpha.com |
2025-04-16 13:49:56 |
Czytaj oryginał (ang.) |
| Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? |
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-04-10 14:30:48 |
Czytaj oryginał (ang.) |
| BROAD ARROW ADDS RARE RUF CTR YELLOWBIRD TO PORSCHE AUCTION IN PARTNERSHIP WITH AIR|WATER |
Broad Arrow Auctions, a Hagerty (NYSE: HGTY) company, has announced an exceedingly rare 1989 RUF CTR Yellowbird, chassis no. W09BT0348KPR06023, to lead its second annual Porsche Auction in partnership with Air|Water. Set for April 26 at the Orange County Fairgrounds in Costa Mesa, California, the single-day auction held within the Air|Water event will once again feature more than 50 desirable Porsches along with a selection of coveted Porsche memorabilia pieces. |
globenewswire.com |
2025-04-09 16:46:00 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 21,806 restricted stock units of the company's common stock to 16 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-19 19:00:00 |
Czytaj oryginał (ang.) |
| Ultragenyx to Participate at Investor Conferences in March |
NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences. |
globenewswire.com |
2025-02-24 18:30:00 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
NOVATO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 23,760 restricted stock units of the company's common stock to 10 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-19 18:30:00 |
Czytaj oryginał (ang.) |
| AMERICAN SALARS ACQUIRES 18,083 HECTARE BRAZIL HARDROCK LCT PEGMATITE PROPERTY WITH RECENT SAMPLING UP TO 3.72% LI20 AND SIGNIFICANT RARE EARTH ELEMENT VALUES |
VANCOUVER, BC, Feb. 18, 2025 (GLOBE NEWSWIRE) -- AMERICAN SALARS LITHIUM INC. ("AMERICAN SALARS" OR THE "COMPANY") (CSE: USLI, OTC: USLIF, FWB: Z3P, WKN: A3E2NY ) announces that it has entered into a share purchase agreement to acquire all of the outstanding shares of 1447377 BC Ltd. (the “Vendor”) that holds a 100% interest in a highly prospective 18,083 Hectares (180 sq km) Hardrock LCT (“Lithium-Cesium-Tantalum”) Pegmatite Project including Rare Earth Elements (“REE”) and a suite of Critical Minerals (the “Jaguaribe Project”). |
globenewswire.com |
2025-02-18 05:01:00 |
Czytaj oryginał (ang.) |
| Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y |
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year. |
zacks.com |
2025-02-14 12:41:35 |
Czytaj oryginał (ang.) |
| Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript |
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Tazeen Ahmad - Bank of America Salveen Richter - Goldman Sachs Gena Wang - Barclays Yaron Werber - TD Cowen Joon Lee - Truist Securities Jeff Hung - Morgan Stanley Rick Miller - Cantor Fitzgerald Luca Issi - RBC Capital Liisa Bayko - Evercore ISI Operator Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only-mode. |
seekingalpha.com |
2025-02-13 23:53:23 |
Czytaj oryginał (ang.) |
| Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-13 20:30:21 |
Czytaj oryginał (ang.) |
| Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates |
Ultragenyx (RARE) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.52 per share a year ago. |
zacks.com |
2025-02-13 20:11:08 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update |
2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million |
globenewswire.com |
2025-02-13 18:01:00 |
Czytaj oryginał (ang.) |
| Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update |
NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 13, 2025, to discuss its financial results and corporate update for the quarter and the year ending December 31, 2024. |
globenewswire.com |
2025-02-06 18:30:00 |
Czytaj oryginał (ang.) |
| RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study |
Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A. |
zacks.com |
2025-02-06 13:31:10 |
Czytaj oryginał (ang.) |
| Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS |
Modified intent-to-treat group demonstrated +22.7 point (p |
globenewswire.com |
2025-02-05 10:00:00 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
NOVATO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 7,750 restricted stock units of the company's common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of January 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-01-17 18:30:00 |
Czytaj oryginał (ang.) |
| Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside |
In conjunction with the 2025 J.P. Morgan Healthcare Conference, the analyst hosted an investor lunch with Ultragenyx Pharmaceutical Inc RARE. |
benzinga.com |
2025-01-15 16:05:35 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones |
Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89 million |
globenewswire.com |
2025-01-12 13:00:00 |
Czytaj oryginał (ang.) |
| RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use |
EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder. |
zacks.com |
2025-01-07 13:25:42 |
Czytaj oryginał (ang.) |
| Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 AM PT. |
globenewswire.com |
2025-01-06 18:30:00 |
Czytaj oryginał (ang.) |
| European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) |
First and only medicine approved in the EU for paediatric patients aged 6-months to 5 years old with HoFH, an ultrarare, inherited form of high cholesterol First and only medicine approved in the EU for paediatric patients aged 6-months to 5 years old with HoFH, an ultrarare, inherited form of high cholesterol |
globenewswire.com |
2025-01-06 04:00:00 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 15,175 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-20 18:30:00 |
Czytaj oryginał (ang.) |
| RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy |
Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States. |
zacks.com |
2024-12-20 14:31:35 |
Czytaj oryginał (ang.) |
| NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) |
LONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultrarare genetic diseases, today announced that NHS England has implemented the commissioning of Evkeeza (evinacumab) following the National Institute for Health and Care Excellence (NICE) final guidance in September. The use of Evkeeza in eligible people aged 12 years and older will be routinely commissioned by NHS England in line with the NICE TA and will be available in seven hospital trusts in England. In addition, prior approval forms are in place to enable access for children aged 5 to 11 years, via the NHS England Commissioning Medicines for Children policy. |
globenewswire.com |
2024-12-20 05:00:00 |
Czytaj oryginał (ang.) |
| Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome |
Company on track to initiate the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025 Company on track to initiate the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025 |
globenewswire.com |
2024-12-19 18:05:00 |
Czytaj oryginał (ang.) |
| HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT |
PLYMOUTH MEETING, Pa. , Dec. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming Oppenheimer Movers in Rare Disease Summit in New York, NY on Thursday, December 12, 2024, at 9:00 a.m. |
prnewswire.com |
2024-12-03 10:05:00 |
Czytaj oryginał (ang.) |
| Ultragenyx to Participate in Investor Conferences in December |
NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences. |
globenewswire.com |
2024-11-26 18:30:00 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 20,820 restricted stock units of the company's common stock to 13 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-11-20 18:30:00 |
Czytaj oryginał (ang.) |
| AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 |
MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA® as the First Potential Treatment tor IgG4-RD Phase 4 AGILE Data Support Shortening KRYSTEXXA® Infusion Time THOUSAND OAKS, Calif. , Nov. 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C. |
prnewswire.com |
2024-11-14 18:00:00 |
Czytaj oryginał (ang.) |
| Ultragenyx: Ready For More Growth After Q3 Earnings Beat |
Ultragenyx's strong Q3 earnings report, with a 42% YoY revenue increase, has reignited my interest in initiating a starter position in RARE. The company's promising pipeline, including late-stage programs like Setrusumab and DTX401, presents multiple catalysts for future growth and higher valuation. Ultragenyx's $825M cash position and path to profitability by 2026 suggest financial stability, potentially avoiding the need for extensive dilutive financing. |
seekingalpha.com |
2024-11-12 13:12:09 |
Czytaj oryginał (ang.) |
| Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit |
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 |
globenewswire.com |
2024-11-09 12:30:00 |
Czytaj oryginał (ang.) |
| Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates |
RARE reports encouraging third-quarter results, beating earnings and revenue estimates. Product sales increase year over year. |
zacks.com |
2024-11-06 12:45:31 |
Czytaj oryginał (ang.) |
| Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript |
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Chris Raymond - Piper Sandler Tazeen Ahmad - Bank of America Malcolm Kuno - JPMorgan Gena Wang - Barclays Lydia Erdman - Goldman Sachs Maury Raycroft - Jefferies Mehdi Goudarzi - Truist Securities Yaron Werber - TD Cowen Yigal Nochomovitz - Citi Thomas Yip - H.C. Wainwright Jack Allen - Baird Joe Schwartz - Leerink Partners Michael Riad - Morgan Stanley Kristen Kluska - Cantor Fitzgerald Dae Gon Ha - Stifel Operator Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-11-06 00:40:31 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-11-05 21:00:32 |
Czytaj oryginał (ang.) |
| Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates |
Ultragenyx (RARE) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $2.23 per share a year ago. |
zacks.com |
2024-11-05 20:15:15 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update |
Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million |
globenewswire.com |
2024-11-05 18:01:00 |
Czytaj oryginał (ang.) |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
NOVATO, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 22,405 restricted stock units of the company's common stock to six newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of October 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-10-18 20:30:00 |
Czytaj oryginał (ang.) |
| RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag |
Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab. |
zacks.com |
2024-10-08 16:10:20 |
Czytaj oryginał (ang.) |
| RARE's Wilson Disease Candidate Betters Standard Therapy in Study |
Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study. |
zacks.com |
2024-10-04 16:05:20 |
Czytaj oryginał (ang.) |
| Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease |
NOVATO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today reported that the Phase 1/2/3 Cyprus 2+ study of its UX701 gene therapy has demonstrated meaningful clinical activity as well as improvements in copper metabolism in Stage 1. Multiple responders have completely tapered off of standard-of-care treatment with responses seen in all three dose cohorts. The company plans to enroll an additional cohort in Stage 1 at a moderately increased dose and with an optimized immunomodulation regimen to enhance the efficiency and efficacy of the gene therapy, with the objective of having the majority of patients come off of standard-of-care treatment before selecting a dose for the randomized placebo-controlled stage of the study. |
globenewswire.com |
2024-10-03 20:30:00 |
Czytaj oryginał (ang.) |
| Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting |
NOVATO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will present seven abstracts related to its ongoing late-stage program evaluating setrusumab (UX143) and osteogenesis imperfecta (OI), including a late-breaker oral presentation of the 14-month data from the Phase 2/3 Orbit study, at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. The meeting is being held September 27-30, 2024, in Toronto, Canada. |
globenewswire.com |
2024-09-26 12:00:00 |
Czytaj oryginał (ang.) |